CDK versus GSK-3 inhibition: a purple haze no longer?

被引：23

作者：

Fischer, PM ^{[1
]}

机构：

[1] Cyclacel Ltd, Dundee DD1 5JJ, Scotland

来源：

CHEMISTRY & BIOLOGY | 2003年 / 10卷 / 12期

关键词：

D O I：

10.1016/j.chembiol.2003.12.009

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The ubiquitous ATP binding site offers a global target for protein kinase inhibitors. The corollary is that molecular selectivity with such agents may be difficult to achieve and ascertain. A relevant example is discussed in terms of design and biomedical rationale.

引用

收藏

页码：1144 / 1146

页数：3

相关论文

共 18 条

[1] Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors [J].

Bertrand, JA ;

Thieffine, S ;

Vulpetti, A ;

Cristiani, C ;

Valsasina, B ;

Knapp, S ;

Kalisz, HM ;

Flocco, M .

JOURNAL OF MOLECULAR BIOLOGY, 2003, 333 (02) :393-407

[2] Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 [J].

Bhat, R ;

Xue, YF ;

Berg, S ;

Hellberg, S ;

Ormö, M ;

Nilsson, Y ;

Radesäter, AC ;

Jerning, E ;

Markgren, PO ;

Borgegård, T ;

Nylöf, M ;

Giménez-Cassina, A ;

Hernández, F ;

Lucas, JJ ;

Díaz-Nido, J ;

Avila, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) :45937-45945

[3] The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases [J].

Brown, NR ;

Noble, MEM ;

Endicott, JA ;

Johnson, LN .

NATURE CELL BIOLOGY, 1999, 1 (07) :438-443

[4] Protein kinases - the major drug targets of the twenty-first century? [J].

Cohen, P .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315

[5] Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate [J].

Davies, TG ;

Tunnah, P ;

Meijer, L ;

Marko, D ;

Eisenbrand, G ;

Endicott, JA ;

Noble, MEM .

STRUCTURE, 2001, 9 (05) :389-397

[6]

de la Fuente C, 2003, CURR HIV RES, V1, P131

[7] CDK inhibitors in clinical development for the treatment of cancer [J].

Fischer, PM ;

Gianella-Borradori, A .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (06) :955-970

[8] Pharmacological inhibitors of cyclin-dependent kinases [J].

Knockaert, M ;

Greengard, P ;

Meijer, L .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (09) :417-425

[9] Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease -: A property common to most cycline-dependent kinase inhibitors? [J].

Leclerc, S ;

Garnier, M ;

Hoessel, R ;

Marko, D ;

Bibb, JA ;

Snyder, GL ;

Greengard, P ;

Biernat, J ;

Wu, YZ ;

Mandelkow, EM ;

Eisenbrand, G ;

Meijer, L .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (01) :251-260

[10] The protein kinase complement of the human genome [J].

Manning, G ;

Whyte, DB ;

Martinez, R ;

Hunter, T ;

Sudarsanam, S .

SCIENCE, 2002, 298 (5600) :1912-+